Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Early use of abiraterone and radium-223 in metastatic prostate cancer.

Cursano MC, Santini D, Iuliani M, Paganelli G, De Giorgi U.

Lancet Oncol. 2019 May;20(5):e228. doi: 10.1016/S1470-2045(19)30226-8. No abstract available.

PMID:
31044705
2.

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.

Peters ML, de Meijer C, Wyndaele D, Noordzij W, Leliveld-Kors AM, van den Bosch J, van den Berg PH, Baka A, Gaultney JG.

Appl Health Econ Health Policy. 2018 Feb;16(1):133-143. doi: 10.1007/s40258-017-0350-x. Erratum in: Appl Health Econ Health Policy. 2018 Jan 4;:.

3.

Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.

Tassinari D, Cherubini C, Roudnas B, Tamburini E, Drudi F, Bianchi E, Fantini M, Montanari F, Sartori S.

Rev Recent Clin Trials. 2018;13(3):226-237. doi: 10.2174/1574887113666180404120540.

PMID:
29623850
4.

Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide.

Jiménez Romero ME, Díez Farto S, Navarro Serrato JS, Canelón Castillo E, Revelo Cadena I.

Exp Oncol. 2018 Jun;40(2):144-148.

PMID:
29949528
5.

eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.

Shore ND, Tutrone RF, Mariados NF, Nordquist LT, Mehlhaff BA, Steere KJ, Harrelson SS.

Clin Genitourin Cancer. 2018 Apr;16(2):149-154. doi: 10.1016/j.clgc.2017.10.022. Epub 2017 Nov 7.

6.

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators.

Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.

PMID:
27473888
7.

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.

Tucci M, Caffo O, Buttigliero C, Cavaliere C, D'aniello C, Di Maio M, Kinspergher S, Maines F, Rizzo M, Rossetti S, Veccia A, Scagliotti GV, Facchini G.

Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7. Review.

PMID:
30738364
8.

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer.

Zobniw CM, Causebrook A, Fong MK.

Res Rep Urol. 2014 Aug 5;6:97-105. doi: 10.2147/RRU.S29003. eCollection 2014. Review.

9.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
10.

Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.

Pharmacoeconomics. 2017 Apr;35(4):415-424. doi: 10.1007/s40273-016-0457-1. Review.

11.

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223.

Mukherji D, El Dika I, Temraz S, Haidar M, Shamseddine A.

Ther Clin Risk Manag. 2014 May 23;10:373-80. doi: 10.2147/TCRM.S45667. eCollection 2014. Review.

12.

Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer.

Unda-Urzaiz M, Sousa-Campo R, Rodríguez-Antolín A, Silva-Marins C, Juárez-Soto A, Miñana-López B, Figueiredo-de Castro A, Cozar-Olmos JM.

Actas Urol Esp. 2018 May;42(4):227-237. doi: 10.1016/j.acuro.2017.05.005. Epub 2017 Jul 12. English, Spanish.

PMID:
28711312
13.

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ; Abiraterone Global EAP Investigators.

Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.

PMID:
25242048
14.

Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.

McCool R, Fleetwood K, Glanville J, Arber M, Goodall H, Naidoo S.

Value Health. 2018 Oct;21(10):1259-1268. doi: 10.1016/j.jval.2018.03.012. Epub 2018 May 4. Review.

PMID:
30314628
15.

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy.

Gartrell BA, Saad F.

Ther Adv Urol. 2015 Aug;7(4):194-202. doi: 10.1177/1756287215592288. Review.

16.

Early use of abiraterone and radium-223 in metastatic prostate cancer.

Hindié E, Morgat C.

Lancet Oncol. 2019 May;20(5):e229. doi: 10.1016/S1470-2045(19)30235-9. No abstract available.

PMID:
31044706
17.

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30275-6. doi: 10.1016/j.clgc.2017.08.020. [Epub ahead of print]

18.

Therapy Update for Metastatic Castration-Resistant Prostate Cancer.

Dinh JA, Baker D, Chahal M.

Consult Pharm. 2016;31(10):581-592. Review.

PMID:
27725068
19.
20.

The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.

Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF.

Cancer Treat Rev. 2018 Jul;68:25-37. doi: 10.1016/j.ctrv.2018.04.014. Epub 2018 May 3. Review.

Supplemental Content

Support Center